Tonix Pharmaceuticals Holding Corp. (TNXP)
Stock analysis · NASDAQ · Healthcare · Biotechnology
Tonix Pharmaceuticals Holding Corp. (TNXP) is a publicly traded company in the Healthcare sector. Latest price: $5.10. Market cap $87.47M. Trailing PE -0.39. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX…
Valuation
| P/E (TTM) | -0.39× |
|---|---|
| P/S (TTM) | 3.01× |
| P/B | 0.38× |
| P/FCF (TTM) | -0.55× |
| EV / EBITDA | 0.56× |
| EV / Sales | -3.01× |
| Earnings Yield | -188.20% |
| Free Cash Flow Yield | -182.79% |
Fundamentals
| Enterprise Value | -$87.49M |
|---|---|
| Net Income (TTM) | -$164.62M |
| Free Cash Flow (TTM) | -$159.89M |
| Net Debt | -$174.96M |
| Working Capital | $172.65M |
| Gross Margin | 80.25% |
| Operating Margin | -568.43% |
| Net Margin | -548.64% |
| Return on Equity | -68.99% |
| Return on Invested Capital | -74.00% |
Peers
Recent News
- Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Pati…
- Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
- A New Fibromyalgia Drug Deal Reaches 21 Million More Medicare Lives. Her Own Plan Could Still Decide What She Pays
- Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain
- Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
Related
Browse more tickers: sitemap